UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

 $(Amendment No. 1)^1$

Kura Oncology, Inc.
(Name of Issuer)
Common Stock, par value \$0.0001
(Title of Class of Securities)
50127T109
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
☑ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, <i>see</i> the <i>Notes</i>).

1	NAME OF REPOR	TING PERSON	
	Biotechnolog	y Value Fund, L.P.	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		662,286	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		662,286	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	662,286		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	1.0%		
12	TYPE OF REPORT	TING PERSON	
	PN		

1	NAME OF REPOR	TING PERSON	
	BVF I GP LL	C	
2	CHECK THE APPI	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
	CEC LICE ONLY		
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	-
	_,		
NUMBER OF	Delaware 5	SOLE VOTING POWER	_
SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING PERSON WITH	7	662,286 SOLE DISPOSITIVE POWER	
PERSON WITH	/	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		900 000	
9	ACCDECATE AM	662,286 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGATE AW	OUNT DENEFICIALLY OWNED BY EACH REPORTING PERSON	
	662,286		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
11	I LICEIVI OF CLF	100 KLI KLOLITILD DI AMOUNI IN KOW (3)	
	1.0%		
12	TYPE OF REPORT	TING PERSON	
	00		
	00		

1	NAME OF REPORT	TING PERSON	
	Biotechnology	Value Fund II, L.P.	
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR 1	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 479,517	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0 shares	
	8	SHARED DISPOSITIVE POWER 479,517	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA Less than 1%	SS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORT	ING PERSON	

1	NAME OF REPORT	TING PERSON	
	BVF II GP LL	C	
2		COPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		479,517	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		479,517	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	479,517		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	Less than 1%		
12	TYPE OF REPORT	ING PERSON	
	00		

1	NAME OF REPORT	TING PERSON	
	Biotechnology	7 Value Trading Fund OS LP	
2	CHECK THE APPR	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	_
	Cayman Islan	ds	
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 80,458	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0 shares	
	8	SHARED DISPOSITIVE POWER 80,458	
9	AGGREGATE AMO 80,458	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA Less than 1%	SS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORT PN	ING PERSON	

1	NAME OF REPOR	TING PERSON	
	BVF Partners	OS Ltd.	
2	CHECK THE APPE	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
			. ,
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Cayman Islan		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		80,458	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		80,458	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	80,458		
10	CHECK BOX IF TI	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	Less than 1%		
12	TYPE OF REPORT	ING PERSON	
	CO		

1	NAME OF REPORT	TING PERSON	
	BVF GP HOL	DINGS LLC	
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR F	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 1,141,803	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0 shares	
	8	SHARED DISPOSITIVE POWER 1,141,803	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORTI	ING PERSON	

	(a) ⊠ (b) □
3 SEC USE ONLY	
4 CITIZENSHIP OR PLACE OF ORGANIZATION	
Delaware	
NUMBER OF 5 SOLE VOTING POWER SHARES	
BENEFICIALLY 0 shares	
OWNED BY 6 SHARED VOTING POWER EACH	
REPORTING 1,245,912	
PERSON WITH 7 SOLE DISPOSITIVE POWER	
0 shares	
8 SHARED DISPOSITIVE POWER	
1,245,912	
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
1,245,912	
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
1.9%	
12 TYPE OF REPORTING PERSON	
PN, IA	

1	NAME OF REPORT	TING PERSON	
	BVF Inc.		
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR F	LACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 1,245,912	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0 shares	
	8	SHARED DISPOSITIVE POWER 1,245,912	
9		DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	1,245,912 CHECK BOX IF TH	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLAS	SS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORTI	NG PERSON	
	CO		

1	NAME OF REPORT	TINC DEDSON	
1	NAME OF REPORT	ING PERSON	
	Mark N. Lamp	pert	
2	_	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
2		OTRINIE BOX II A WEWDER OF A GROOT	(a) ⊡ (b) □
			(6) =
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	United States		
NUMBER OF	5	SOLE VOTING POWER	
SHARES		0.1	
BENEFICIALLY OWNED BY	6	0 shares SHARED VOTING POWER	
EACH	0	SHARED VOTING POWER	
REPORTING		1,245,912	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	,	SOLL BISTOSITIVE TOWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		1,245,912	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	4.0.4		
10	1,245,912	TE A CODEC AME A MOUNTE IN DOLL (O) DWGI LIDEG CEDMAIN GUA DEC	
10	CHECK BOX IF IF	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
11	LENGENT OF CERT	55 12.12.52.1125 51 111.15511 11.11611 (5)	
	1.9%		
12	TYPE OF REPORT	ING PERSON	
	IN		

Item 1(a). Name of Issuer:

Kura Oncology, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

3033 Science Park Road, Suite 220 San Diego, California 92121

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC ("BVF2 GP") 44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.0001 per share (the "Shares")

Item 2(e). CUSIP Number:

50127T109

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section $3(c)(14)$ of the Investment Company Act.
(j)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership.

(a) Amount beneficially owned:

As of the close of business on December 31, 2020, (i) BVF beneficially owned 662,286 Shares, (ii) BVF2 beneficially owned 479,517 Shares, and (iii) Trading Fund OS beneficially owned 80,458 Shares.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 662,286 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 479,517 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 80,458 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 1,141,803 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 1,245,912 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and a certain Partners managed account (the "Partners Managed Account"), including 23,651 Shares held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 1,245,912 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 1,245,912 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on 65,953,796 Shares outstanding as of December 11, 2020, as disclosed in the Issuer's Prospectus on Form 424B5 filed with the Securities and Exchange Commission on December 9, 2020, and a press release filed by the Issuer on December 11, 2020.

As of the close of business on December 31, 2020, (i) BVF beneficially owned approximately 1.0% of the outstanding Shares, (ii) BVF2 beneficially owned less than 1% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 1.0% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 1.7% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 1.9% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or

Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on March 16, 2020.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2021 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP By: BVF Partners L.P., its investment manager BVF I GP LLC., its general partner BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF I GP LLC BVF GP HOLDINGS LLC** /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. BVF II GP LLC, its general partner By: BVF Inc., its general partner /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF II GP LLC** BVF INC. By: /s/ Mark N. Lampert By: /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF PARTNERS OS LTD. /s/ Mark N. Lampert

BVF Partners L.P., its sole member BVF Inc., its general partner

By: /s/ Mark N. Lampert Mark N. Lampert

President

17

MARK N. LAMPERT